.Pharmacolibrary.Drugs.ATC.J.J05AR26 .Pharmacolibrary.Drugs.ATC.J.J05AR26| name: | DarunavirAndRitonavir |
| ATC code: | J05AR26 | route: | oral |
| n-compartments | 2 |
Darunavir is a protease inhibitor used in combination with ritonavir, a pharmacokinetic enhancer, for the treatment of Human Immunodeficiency Virus (HIV) infection. The ritonavir component boosts darunavir levels by inhibiting CYP3A-mediated metabolism. This fixed-dose combination is approved as antiretroviral therapy for HIV-1 infection.
Pharmacokinetic parameters reported for healthy adult subjects; darunavir/ritonavir 800 mg/100 mg administered orally once daily.
Dickinson, L, et al., & Boffito, M (2020). Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. The Journal of antimicrobial chemotherapy 75(3) 628–639. DOI:10.1093/jac/dkz479 PUBMED:https://pubmed.ncbi.nlm.nih.gov/31754703
Dickinson, L, et al., & Siccardi, M (2016). Simulation of the impact of rifampicin on once-daily darunavir/ritonavir pharmacokinetics and dose adjustment strategies: a population pharmacokinetic approach. The Journal of antimicrobial chemotherapy 71(4) 1041–1045. DOI:10.1093/jac/dkv439 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26712906
Schalkwijk, S, et al., & Russel, FGM (2018). Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling. Clinical pharmacokinetics 57(6) 705–716. DOI:10.1007/s40262-017-0583-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28744795